DekaBank Deutsche Girozentrale Raises Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

DekaBank Deutsche Girozentrale raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 276,974 shares of the medical equipment provider’s stock after purchasing an additional 339 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zimmer Biomet were worth $25,445,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Washington Trust Advisors Inc. purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $30,000. Accent Capital Management LLC purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $35,000. Cullen Frost Bankers Inc. lifted its stake in Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares during the last quarter. Finally, Hilltop National Bank purchased a new stake in Zimmer Biomet in the second quarter valued at approximately $42,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.2%

Shares of ZBH stock opened at $103.87 on Thursday. The business’s fifty day moving average price is $101.83 and its 200 day moving average price is $97.72. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The firm has a market capitalization of $20.58 billion, a PE ratio of 25.27, a P/E/G ratio of 2.36 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the prior year, the company posted $2.01 earnings per share. Zimmer Biomet’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research note on Thursday, September 18th. Evercore ISI cut their price target on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research note on Tuesday, October 7th. BTIG Research upped their price target on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $111.94.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.39% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.